Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCERTAIN: Saruparib and Darolutamide Prior to Radical Prostatectomy in Prostate Cancer
NCT05938270Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, randomised, open-label trial of saruparib in prostate cancer (PCa) (4 arms), sponsored by AstraZeneca. Primary endpoint: Fold change in % γH2AX positive cells from baseline value in tumour samples at 21 days. Started Sep 2023; status: completed.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05938270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938270.